MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee

NCT05618782 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 518

Last updated 2025-11-20

Study results available
· View outcomes & findings →

Summary

This is a phase 2, randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee.

Conditions

Interventions

DRUG

LEVI-04

LEVI-04, a fully human chimeric fusion protein that combines the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75 NTR), for the treatment of chronic pain.

OTHER

Placebo

Saline vehicle

Sponsors & Collaborators

  • Nordic Bioscience Clinical Development (NBCD)

    collaborator UNKNOWN

  • Levicept

    lead INDUSTRY

Principal Investigators

  • Simon Westbrook · Levicept

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2024-05-20
Completion
2024-05-20

Countries

  • Czechia
  • Denmark
  • Hong Kong
  • Moldova
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618782 on ClinicalTrials.gov